Get the Stockscreener App
34.89
1.83%
-0.65
Tonix Pharmaceuticals Holding Corp stock is traded at $34.89, with a volume of 1.92M.
It is down -1.83% in the last 24 hours and down -5.68% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$35.54
Open:
$35.15
24h Volume:
1.92M
Relative Volume:
1.66
Market Cap:
$277.66M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-3.0986
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+7.82%
1M Performance:
-5.68%
6M Performance:
+3.35%
1Y Performance:
-49.43%
1-Day Range:
$33.81
$35.50
1-Week Range:
$30.82
$36.20
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
34.89 | 277.66M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Shows Breakthrough Results, FDA Decision Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP St - GuruFocus
Tonix Pharmaceuticals Announces Appointment of Commercial - GlobeNewswire
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter - citybuzz -
Tonix Pharmaceuticals Announces Appointment of Commercial Indust - GuruFocus
Tonix Pharmaceuticals Appoints James “Jim” Hunter To Board - citybiz
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP Stock News - GuruFocus
Tonix Pharma Appoints James Hunter to Board - TipRanks
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion? (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors | TNXP Stock News - GuruFocus
Tonix Strengthens Board with 40-Year Pharma Veteran as FDA Decision on Fibromyalgia Drug Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Sh - GuruFocus
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals stock falls after announcing $225 million share offerings - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Drops After $500M Shelf Filing - GuruFocus
Tonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares Tumble - Benzinga
Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic By Stocktwits - Investing.com India
Oxford Industries, GameStop, Boeing And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals (TNXP) Files for $500M Mixed Securities Shelf | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Plans Potential Share Sale of Up to $150 Million; Stock Falls Premarket - MarketScreener
Tonix Pharma Signs Major Sales Agreements for Funding - TipRanks
Tonix Pharmaceuticals Holding May Sell Up To $150 Million In Common Stock - marketscreener.com
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention - citybuzz -
(TNXP) Long Term Investment Analysis - news.stocktradersdaily.com
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO Int - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention - The Manila Times
Tonix Fibromyalgia Drug Faces Critical FDA Decision: CEO to Present Latest Data at BIO 2025 - Stock Titan
Analysis of Tonix Pharmaceuticals (TNXP) Stock: Performance, News for June 2025 - Investing.com India
Tonix Pharmaceuticals doses first patient in Phase 2 OASIS trial for acute stress reaction - Proactive Investors
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 - The Manila Times
Tonix New Fibromyalgia Drug Shows Dual Sleep and Pain Benefits at EULAR 2025 | TNXP Stock News - Stock Titan
Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World
Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World
Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - Revista ADVFN
How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com
Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):